...
首页> 外文期刊>Biotechnology Law Report >Triantafyllos Tafas v. Jon W. Dudas et al., 1:07cv846 (JCC), Consolidated with SmithKline Beecham Corp. et al. v. Jon W. Dudas et al., 1:07cv1008 (JCC)
【24h】

Triantafyllos Tafas v. Jon W. Dudas et al., 1:07cv846 (JCC), Consolidated with SmithKline Beecham Corp. et al. v. Jon W. Dudas et al., 1:07cv1008 (JCC)

机译:Triantafyllos Tafas诉Jon W. Dudas等,1:07cv846(JCC),与SmithKline Beecham Corp.等合并。 v Jon W.Dudas等人,1:07cv1008(JCC)

获取原文
获取原文并翻译 | 示例
           

摘要

This matter is before the Court on: (1) Plaintiffs SmithKline Beecham Corporation and Glaxo Group Limited’sn(“GSK”) Motion for a Temporary Restraining Order (“TRO”) and Preliminary Injunction; (2) Defendants Jon W.nDudas and United States Patent and Trademark Office’s (“PTO”) Motion to Strike Exhibit E of the Memorandumnin Support of GSK’s Motion; (3) the Motion of Amicus Curiae American Intellectual Property Law Associationn(“AIPLA”) for Leave to File its Brief in Support of GSK’s Motion; (4) HEXAS, LLC (“Hexas”), The RoskampnInstitute, and Tikvah Therapeutics, Inc.’s (“Tikvah”) Joint Motion in Support of Motion for Leave to File AmicinCuriae Brief in Support of GSK’s Motion; and (5) the Motion of Amicus Curiae Elan Pharmaceutical Corp. fornLeave to File its Brief in Support of GSK’s Motion. For the reasons stated below, the Court will grant GSK’s motion,ndeny the PTO’s motion, and grant the motions for leave to file as amici.
机译:此事已提交法院处理:(1)原告SmithKline Beecham Corporation和葛兰素集团有限公司的临时限制令(TRO)和临时禁令的动议; (2)被告人乔恩·温杜斯(Jon W.nDudas)和美国专利商标局(“ PTO”)的动议,以罢工的方式向G的动议的备忘录备忘录E展示附表E; (3)Amicus Curiae美国知识产权法协会(AIPLA)的动议,要求其提起支持GSK动议的摘要; (4)HEXAS,LLC(“ Hexas”),RoskampnInstitute和Tikvah Therapeutics,Inc.(“ Tikvah”)联合动议,支持动议许可AmicinCuriae提起支持GSK动议的摘要; (5)Amicus Curiae Elan Pharmaceutical Corp.的动议forLeLeave提交其摘要以支持GSK的动议。基于以下原因,法院将批准葛兰素史克的动议,否认专利商标局的动议,并准许这些动议以阿米奇的身份提起诉讼。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号